TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19765233

Group type: EXPERIMENTAL
Intervention: CRT ON
Number of subjects: 72

Group type: COMPARATOR
Intervention: CRT OFF
Number of subjects: 72
Study: 16625987

Group type: EXPERIMENTAL
Intervention: Generic efavirenz capsule (Ranbaxy-Efavirenz)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Innovator efavirenz capsule (Sustiva)
Number of subjects: 41
Study: 15541407

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (600 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg)
Number of subjects: 0
Study: 11421247

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9247181

Group type: EXPERIMENTAL
Intervention: 19 mm HP (HP19)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 21 mm HP (HP21)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 19 mm SJM (SJM19)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 21 mm SJM (SJM21)
Number of subjects: 65
Study: 8329255

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg kg‐1
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 3539508

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 methyl sulphonylamide
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: 1.0 mg PGE1 methyl ester
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: 30 mg 9-methylene PGE2 free acid
Number of subjects: 627

Group type: COMPARATOR
Intervention: 0.5 mg 15-methyl PGF2 alpha
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Single medium-sized laminaria tent
Number of subjects: 627
Study: 29700350

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Menopause Education Control (MEC)
Number of subjects: 197
Study: 27590313

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - three 1 hour sessions per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (AC) - three 30 minute walking sessions per week
Number of subjects: 0
Study: 25282033

Group type: EXPERIMENTAL
Intervention: Dual-chamber setting
Number of subjects: 462

Group type: COMPARATOR
Intervention: Single-chamber setting
Number of subjects: 462
Study: 22781527

Group type: EXPERIMENTAL
Intervention: Ultrasound group (n = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 102
Study: 20035347

Group type: EXPERIMENTAL
Intervention: P12 (12 mmHg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: P20 (20 mmHg)
Number of subjects: 67
Study: 19065890

Group type: EXPERIMENTAL
Intervention: Combined therapy of Shehuang Paste (SHP) and colonic dialysis with herbal medicine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional basic therapy (placebo paste and colonic dialysis with normal saline)
Number of subjects: 120
Study: 15755701

Group type: EXPERIMENTAL
Intervention: Aprotinin (1000000 KIU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12587536

Group type: EXPERIMENTAL
Intervention: Dopamine-agonist therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (healthy controls and dopamine-agonist treated women)
Number of subjects: 87
Study: 9673663

Group type: EXPERIMENTAL
Intervention: Robot-aided functional imaging with a portable robotic device generating forces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neuroimaging results
Number of subjects: 8
Study: 7640116

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v. given 10 min before induction of anaesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v. group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 2751919

Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 797447

Group type: EXPERIMENTAL
Intervention: Dianhydrogalactitol (30 mg/m2/day for 5 days)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: VP-16-213 (130 mg/m2 on Days 1, 3, and 5)
Number of subjects: 58
Study: 31980201

Group type: EXPERIMENTAL
Intervention: Reciproc with XP-endo Finisher (XPF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reciproc without XP-endo Finisher (XPF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProTaper Next with XP-endo Finisher (XPF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ProTaper Next without XP-endo Finisher (XPF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CEC-Reciproc-XPF
Number of subjects: 80

Group type: COMPARATOR
Intervention: TEC and CEC cavities
Number of subjects: 80
Study: 31484582

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional administration of oxygen through a Venturi mask (Control)
Number of subjects: 200
Study: 28504995

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) - 3 cycles: 5 minutes ischemia/5 minutes reperfusion induced by an ischemia cuff applied on the thigh
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control therapy without RIPC
Number of subjects: 53
Study: 25888246

Group type: EXPERIMENTAL
Intervention: HER2+ hormone receptor-positive (HR+) patients
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: HER2+ hormone receptor-negative (HR-) patients
Number of subjects: 1260
Study: 23503449

Group type: COMPARATOR
Intervention: Fasting conditions (400 mg posaconazole)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal-fat meal (400 mg posaconazole)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-fat meal (400 mg posaconazole)
Number of subjects: 16
Study: 21810825

Group type: EXPERIMENTAL
Intervention: Point-of-care pocket-sized echocardiography (POCKET)
Number of subjects: 108
Study: 19500403

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Physical Exercise
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Combined CBT and Physical Exercise
Number of subjects: 325

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 325
Study: 16448568

Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 14745853

Group type: EXPERIMENTAL
Intervention: Community-based oncology support program
Number of subjects: 169

Group type: COMPARATOR
Intervention: High depression burden group
Number of subjects: 169

Group type: COMPARATOR
Intervention: No depression burden group
Number of subjects: 169
Study: 11126352

Group type: EXPERIMENTAL
Intervention: Family therapy as part of an intervention program for childhood obesity, including behavior modification.
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1322
Study: 9004827

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actuarial approach to treatment benefits
Number of subjects: 0
Study: 1562431

Group type: EXPERIMENTAL
Intervention: Slotted nails (Grosse‐Kempf nail and AO/ASIF universal femoral nail)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-slotted nails (Grosse‐Kempf nail)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control bone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Slotted nails
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-slotted nails
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Slotted nails and Non-slotted nails
Number of subjects: 46
Study: 2866134

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once at night
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 183
Study: 31712013

Group type: COMPARATOR
Intervention: Prostaglandin analogue (PGA) monotherapy (control group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Washout group (discontinue PGA monotherapy)
Number of subjects: 87
Study: 29353367

Group type: EXPERIMENTAL
Intervention: Annual clinical breast exam (CBE)
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Annual mammogram
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Routine source of care, confidence to use healthcare services, perceived expectations from family members and healthcare providers, motivation to comply with expectations
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Cost-related access to care
Number of subjects: 859

Group type: COMPARATOR
Intervention: Black YBCS
Number of subjects: 859
Study: 28881339

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Baseline glomerular filtration rate (GFR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Interstitial B- and T-cell infiltrates
Number of subjects: 33
Study: 26314293

Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 0
Study: 24573586

Group type: COMPARATOR
Intervention: Ligation with section of the saphenous arch (Group C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Simple ligation of the saphenous vein without sectioning of its arch (Group L)
Number of subjects: 45
Study: 21519282

Group type: EXPERIMENTAL
Intervention: Individually tailored behavioral intervention for nonadherence
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 14
Study: 18793584

Group type: EXPERIMENTAL
Intervention: Random effects model
Number of subjects: 0
Study: 12875580

Group type: EXPERIMENTAL
Intervention: Betahistine (BH) 48 mg daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Flunarizine (FL) 10 mg daily
Number of subjects: 52
Study: 11037800

Group type: EXPERIMENTAL
Intervention: Desipramine (Norpramin)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Lamotrigine (Lamictal)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 8854285

Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFA) supplementation (Linoleic acid 596 mg/day and alpha-linolenic acid 855 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study: 1734694

Group type: EXPERIMENTAL
Intervention: 1.5% sodium tetradecyl sulfate (STD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1% polidocanol
Number of subjects: 52
Study: 6716071

Group type: EXPERIMENTAL
Intervention: 20-minute videotape induction
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Pamphlet induction
Number of subjects: 460

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 460
Study: 2937638

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30571591

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: American Heart Association diet
Number of subjects: 100
Study: 26878676

Group type: EXPERIMENTAL
Intervention: Apoaequorin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 25789633

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (ASA) prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control event rate (CERmin) and minimum event rate for treatment (MERT) approaches
Number of subjects: 0
Study: 24278962

Group type: EXPERIMENTAL
Intervention: Indirect posterior composite resin restoration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Direct posterior composite resin restoration
Number of subjects: 29
Study: 20667429

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 110

Group type: COMPARATOR
Intervention: 100% oxygen (placebo)
Number of subjects: 110
Study: 18405079

Group type: EXPERIMENTAL
Intervention: Monomorphemic words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prefixed words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prefixed pseudo‐words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grammatical (word‐formation) rules
Number of subjects: 0
Study: 16606390

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with AV search hysteresis (AVSH)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Single-chamber pacing (VVI)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with AVSH
Number of subjects: 1530
Study: 14509886

Group type: EXPERIMENTAL
Intervention: Retrojugular approach (RJA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional (medial) approach
Number of subjects: 100
Study: 11004426

Group type: EXPERIMENTAL
Intervention: Diamicron(R)MR (30-120 mg/day)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Diamicron(R) (80-320 mg/day)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 800
Study: 8608520

Group type: EXPERIMENTAL
Intervention: Imipenem plus vancomycin (500 mg every 6 hours of imipenem/cilastatin and 1 g every 12 hours of vancomycin)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Aztreonam plus vancomycin (2 g every 6 hours of aztreonam and 1 g every 12 hours of vancomycin)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Imipenem regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Aztreonam regimen
Number of subjects: 300
Study: 1476032

Group type: EXPERIMENTAL
Intervention: Food hypersensitivity (identified by double-blind placebo-controlled food challenges)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: IgE-mediated mast cell and mononuclear cell activation
Number of subjects: 320
Study: 6475712

Group type: EXPERIMENTAL
Intervention: Permanent pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 31818409

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and low‐dose dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pomalidomide and low‐dose dexamethasone
Number of subjects: 0
Study: 27982160

Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Individual Intervention (II)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 72
Study: 26234491

Group type: EXPERIMENTAL
Intervention: HA/PCL + Ag NFMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCL NFMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: HA/PCL NFMs
Number of subjects: 0
Study: 23102711

Group type: EXPERIMENTAL
Intervention: Individualized interdisciplinary case conference including their GP
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Patient/caregiver education about pain management
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Educational outreach visiting for GPs about pain management
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control condition (current palliative care)
Number of subjects: 461
Study: 20890699

Group type: EXPERIMENTAL
Intervention: Total synovectomy and total knee arthroplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total knee arthroplasty alone (Control)
Number of subjects: 50
Study: 19851234

Group type: EXPERIMENTAL
Intervention: Intervention tailoring activities
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intervention tailoring
Number of subjects: 2
Study: 17091416

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: No acupuncture (Control)
Number of subjects: 100
Study: 15207416

Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg daily (in divided doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg at bedtime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Promazine 50 mg daily (in divided doses)
Number of subjects: 60
Study: 11719836

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 59
Study: 9521941

Group type: EXPERIMENTAL
Intervention: PNCRM7
Number of subjects: 212

Group type: COMPARATOR
Intervention: DTP/HbOC
Number of subjects: 212
Study: 7976645

Group type: EXPERIMENTAL
Intervention: High oncotic pressure (HOP; 26‐30 mmHg) treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal oncotic pressure (NOP; 22‐26 mmHg) treatment
Number of subjects: 18
Study: 2917587

Group type: EXPERIMENTAL
Intervention: 50 mg pipequaline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1101902

Group type: EXPERIMENTAL
Intervention: Diphenoxylate 5 mg single oral dose
Number of subjects: 10
Study: 31544950

Group type: EXPERIMENTAL
Intervention: 15-week progressive resistance exercise intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Relaxation intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls (25 women)
Number of subjects: 75
Study: 29070159

Group type: EXPERIMENTAL
Intervention: Self-etch strategy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Etch-and-rinse strategy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adhesion strategy influence
Number of subjects: 44
Study: 25744325

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Psycho-education (control group)
Number of subjects: 43
Study: 23720992

Group type: EXPERIMENTAL
Intervention: OPD-CA interviews
Number of subjects: 39
Study: 21453467

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral zinc sulfate-topical corticosteroid combination
Number of subjects: 35
Study: 19700948

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 25-80 mg/day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 92
Study: 16409328

Group type: EXPERIMENTAL
Intervention: ProFile rotary Nickel‐Titanium (Ni‐Ti) instruments
Number of subjects: 48

Group type: COMPARATOR
Intervention: H‐files combined with Gates‐Glidden (GG) drills
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AH26 sealer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endion sealer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Roth 811 sealer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Roekoseal sealer
Number of subjects: 48
Study: 15307699

Group type: EXPERIMENTAL
Intervention: Luohuo capsule (LHC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Beijing Hypotension No. 0
Number of subjects: 90
Study: 11175492

Group type: EXPERIMENTAL
Intervention: Etofibrate (500 mg twice daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controlled-release niacin (500 mg twice daily)
Number of subjects: 25
Study: 9425675

Group type: EXPERIMENTAL
Intervention: Haptic processing of surfaces with different property classes (material, abrupt-surface discontinuity, relative orientation, continuous 3-D surface contour)
Number of subjects: 15
Study: 8356936

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 66
Study: 3667024

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31845131

Group type: EXPERIMENTAL
Intervention: Parent questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental concerns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Examiner-led assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total and individual item scores from the questionnaire and interactive assessment
Number of subjects: 0
Study: 29131677

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 35
Study: 27269043

Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: ubrogepant 25 mg
Number of subjects: 834

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 834
Study: 24888659

Group type: EXPERIMENTAL
Intervention: Maternal xylitol consumption (chewing xylitol gum, 1.8 gram, 66% xylitol by weight, 3 times/day for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60
Study: 24295141

Group type: EXPERIMENTAL
Intervention: practice‐based intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: control group
Number of subjects: 90
Study: 20722676

Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 microg once daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 10 microg once daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 microg once daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 30 microg once daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 microg twice daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 10 microg twice daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 microg twice daily
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Lixisenatide 30 microg twice daily
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 18401602

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate gel (CHX)
Number of subjects: 138

Group type: COMPARATOR
Intervention: calcium hydroxide/camphorated paramonochlorophenol/glycerin paste (CH/CPMC)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 138